Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Neurobiological Technologies, Inc. NTII OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
65/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Neurobiological Technologies, Inc. (NTII) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Financials: revenue is $26M, +35.1%/yr average growth. Net income is $3M, growing at +51%/yr. Net profit margin is 11.9% (healthy). Gross margin is 99.5% (+1.1 pp trend).

Balance sheet: total debt is $0 against $2M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 35.34 (strong liquidity). Debt-to-assets is 0%. Total assets: $3M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future ?/100 (Fail), Income 55/100 (Partial).

NTII SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 55/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NTII

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
NTII: +35.1%/yr revenue is, +51%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
NTII: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet NTII: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 35.34 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
NTII: Gross margin is 99.5% (+1.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
~
INCOME Partial
55/100
NTII: Net profit margin is 11.9%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.000001-0.0001
Volume1.1K
Avg Volume (30D)846
Market Cap$2.7K
Beta (1Y)-410.84
Share Statistics
EPS (TTM)0.12
Shares Outstanding$26.93M
IPO Date1994-10-31
Employees4
CEOJohn B. Stuppin
Financial Highlights & Ratios
Revenue (TTM)$26.35M
Gross Profit$26.22M
EBITDA$3.26M
Net Income$3.12M
Operating Income$3.49M
Total Cash$2.58M
Net Debt$-1.84M
Total Assets$2.58M
Price / Earnings (P/E)0
Price / Sales (P/S)0
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS64124W3043

Price Chart

Track all markets on TradingView
NTII
Neurobiological Technologies, Inc.  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 0.00

People Also View

PHGUF
PHGUF
Pharming Group N.V.
$1.75
+15.89%
 MMIRF
MMIRF
MedMira Inc.
$0.05
+0.00%
 KNBIF
KNBIF
Kane Biotech Inc.
$0.02
-3.64%
 OCTHF
OCTHF
Oxford Cannabinoid Technologies Holdings Plc
$0.00
+0.00%
 HESG
HESG
Health Sciences Group, Inc.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message